THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about this circular or as to the action to be taken, you should consult your stockbroker, registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Zhejiang Taimei Medical Technology Co., Ltd.,** you should at once hand this circular with the enclosed proxy form to the purchaser or transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

太美医疗科技

Zhejiang Taimei Medical Technology Co., Ltd.

浙江太美醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2576)

(1) WORK REPORT OF THE BOARD FOR 2025;
(2) WORK REPORT OF THE SUPERVISORY COMMITTEE FOR 2025;
(3) AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR 2025;
(4) 2025 ANNUAL REPORT;
(5) 2025 PROFIT DISTRIBUTION PLAN;
(6) RE-ELECTION OF THE BOARD;
(7) RE-ELECTION OF THE SUPERVISORY COMMITTEE;
(8) REMUNERATION OF DIRECTORS;
(9) REMUNERATION OF SUPERVISORS;
(10) 2026 FINANCIAL BUDGET;
(11) RE-APPOINTMENT OF AUDITOR;
(12) PROPOSED GRANTING OF A GENERAL MANDATE TO THE BOARD TO ISSUE SHARES;
(13) PROPOSED GRANTING OF A GENERAL MANDATE TO THE BOARD TO REPURCHASE H SHARES;
(14) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND
(15) NOTICE OF THE AGM

Capitalized terms used on this cover page shall have the same meanings as those defined in this circular.

The Company will convene and hold the AGM at 6th Floor, Building 24, Technology Oasis Phase 3, No. 1999 Yishan Road, Minhang District, Shanghai, PRC at 10:00 a.m. on Tuesday, June 23, 2026, the notice of which is set out on pages AGM-1 to AGM-4 of this circular. The proxy form for use at the AGM is enclosed herein, which is also published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.taimei.com).

If you intend to attend the AGM by proxy, you are required to duly complete the accompanying proxy form in accordance with the instructions printed thereon and return the same to the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at 3/F, Building 9, Smart Industry Innovation Park, 36 Changsheng South Road, Jiaxing, Zhejiang, PRC (for holders of Domestic Shares) as soon as possible and in any event not less than 24 hours before the time fixed for the holding of the AGM or any adjournment thereof (as the case may be) (which is 10:00 a.m. on Monday, June 22, 2026 (or other date in the event of any adjournment thereof)). Completion and return of the proxy form will not preclude you from attending and voting in person at the AGM or any adjournment thereof if you so wish.

References to times and dates in this circular are to Hong Kong local times and dates.

June 1, 2026

CONTENTS

Page

DEFINITIONS 1

LETTER FROM THE BOARD 4

APPENDIX I – BIOGRAPHICAL DETAILS OF THE CANDIDATE DIRECTORS I-1

APPENDIX II – BIOGRAPHICAL DETAILS OF THE CANDIDATE SUPERVISORS II-1

APPENDIX III – EXPLANATORY STATEMENT ON THE H SHARE REPURCHASE MANDATE III-1

NOTICE OF THE AGM AGM-1

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"2025 Annual Report"	the annual report of the Company for the year ended December 31, 2025 published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.taimei.com)
"AGM"	the 2025 annual general meeting of the Company to be held at 6th Floor, Building 24, Technology Oasis Phase 3, No. 1999 Yishan Road, Minhang District, Shanghai, PRC at 10:00 a.m. on Tuesday, June 23, 2026 or any adjournment thereof, notice of which is set out on pages AGM-1 to AGM-4 of this circular
"Articles of Association"	the articles of association of the Company, as amended, modified or supplemented from time to time
"associate(s)"	has the meaning ascribed to it under the Listing Rules
"Board" or "Board of Directors"	the board of Directors
"China" or "PRC"	the People's Republic of China, for the purposes of this circular only, excludes Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company"	Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司), a joint stock company with limited liability incorporated in the PRC, the predecessor of which was Jiaxing Taimei Medical Technology Co., Ltd. (嘉興太美醫療科技有限公司), a limited liability company established in the PRC on June 6, 2013, and if the context requires, includes its predecessor
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for in Renminbi
"Group"	the Company and its subsidiaries, or any one of them as the context may require

"H Share(s)"	overseas listed foreign ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange
"Hong Kong dollars" or "HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Latest Practicable Date"	June 1, 2026, being the latest practicable date prior to the publication of this circular for the purpose of ascertaining certain information contained in this circular
"Listing Date"	October 8, 2024, on which the H Shares are first listed and dealings in the H Shares are first permitted to commence on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended, supplemented or otherwise modified from time to time
"PRC Company Law"	the Company Law of the People's Republic of China (《中華人民共和國公司法》), as amended, supplemented or otherwise modified from time to time
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"SFO"	Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
"Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, including both Domestic Shares and H Shares
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules
"Supervisor(s)"	member(s) of the Supervisory Committee

"Supervisory Committee"	the supervisory committee of the Company
"Takeovers Code"	the Codes on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission of Hong Kong, as amended, supplemented or otherwise modified from time to time
"%"	per cent

Note: The English translation of Chinese names of entities included in this circular is prepared for identification purpose only.

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2576)

Executive Directors:
Dr. ZHAO Lu *(Chairman)*
Mr. MA Dong
Mr. ZHANG Hongwei
Mr. LU Yiming
Mr. HUANG Yufei
Ms. NI Xiaomei

Independent Non-executive Directors:
Dr. JIANG Xiao
Dr. LI Zhiguo
Mr. FUNG Che Wai Anthony

Registered Office, Headquarters and Principal Place of Business in the PRC:
3/F, Building 9
Smart Industry Innovation Park
36 Changsheng South Road, Jiaxing
Zhejiang
PRC

Principal place of business in Hong Kong:
19/F, Golden Centre
188 Des Voeux Road Central
Hong Kong

June 1, 2026

To the Shareholders

Dear Sir or Madam,

(1) WORK REPORT OF THE BOARD FOR 2025;
(2) WORK REPORT OF THE SUPERVISORY COMMITTEE FOR 2025;
(3) AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR 2025;
(4) 2025 ANNUAL REPORT;
(5) 2025 PROFIT DISTRIBUTION PLAN;
(6) RE-ELECTION OF THE BOARD;
(7) RE-ELECTION OF THE SUPERVISORY COMMITTEE;
(8) REMUNERATION OF DIRECTORS;
(9) REMUNERATION OF SUPERVISORS;
(10) 2026 FINANCIAL BUDGET;
(11) RE-APPOINTMENT OF AUDITOR;
(12) PROPOSED GRANTING OF A GENERAL MANDATE TO THE BOARD TO ISSUE SHARES;
(13) PROPOSED GRANTING OF A GENERAL MANDATE TO THE BOARD TO REPURCHASE H SHARES;
(14) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND
(15) NOTICE OF THE AGM

I. INTRODUCTION

The AGM will be convened and held at 6th Floor, Building 24, Technology Oasis Phase 3, No. 1999 Yishan Road, Minhang District, Shanghai, PRC at 10:00 a.m. on Tuesday, June 23, 2026.

This circular is intended to provide you with the notice of the AGM (as set out on pages AGM-1 to AGM-4 of this circular) and all information reasonably necessary to enable you to make an informed decision on the resolutions to be presented at the AGM.

II. MATTERS TO BE RESOLVED AT THE AGM

At the AGM, ordinary resolutions will be proposed for the approval of: (1) the work report of the Board for 2025; (2) the work report of the Supervisory Committee for 2025; (3) the audited consolidated financial statements of the Group for 2025; (4) the 2025 Annual Report; (5) the profit distribution plan for 2025; (6) re-election of the Board; (7) re-election of the Supervisory Committee; (8) the remuneration plan for Directors for 2026; (9) the remuneration plan for Supervisors for 2026; (10) the financial budget for 2026; and (11) the re-appointment of the auditor of the Company and the authorization to the Board to determine its remuneration, and special resolutions will also be proposed for the approval of: (12) the proposed granting of a general mandate to the Board to issue Shares; (13) the proposed granting of a general mandate to the Board to repurchase H Shares; and (14) proposed amendments to the Articles of Association.

Ordinary Resolutions

1. Consideration and approval of the work report of the Board for 2025

An ordinary resolution will be proposed at the AGM to consider and approve the work report of the Board for 2025. The report was considered and approved by the Board on April 23, 2026. Details are set out in the "Report of Directors" section of the 2025 Annual Report.

2. Consideration and approval of the work report of the Supervisory Committee for 2025

An ordinary resolution will be proposed at the AGM to consider and approve the work report of the Supervisory Committee for 2025. The report was considered and approved by the Supervisory Committee on April 23, 2026. Details are set out in the "Report of the Supervisory Committee" section of the 2025 Annual Report.

3. Consideration and approval of the audited consolidated financial statements of the Group for 2025

An ordinary resolution will be proposed at the AGM to consider and approve the audited consolidated financial statements of the Group for 2025. The statements were considered and approved by the Board on March 30, 2026. Details are set out in the audited consolidated financial statements contained in the 2025 Annual Report.

4. Consideration and approval of the 2025 Annual Report

An ordinary resolution will be presented at the AGM to consider and approve the 2025 Annual Report. The 2025 Annual Report was approved by the Board on April 23, 2026.

5. Consideration and approval of the profit distribution plan for 2025

Based on the operating results, financial position and future development plan of the Company, the Board did not recommend payment of a final dividend for the year ended December 31, 2025. The 2025 profit distribution plan was considered and approved by the Board on March 30, 2026, and is hereby proposed at the AGM for consideration and approval.

6. Re-election of the Board

An ordinary resolution will be proposed at the AGM to consider and approve the resolution on the re-election and election of Directors of the third session of the Board.

Pursuant to Article 95 of the Articles of Association, Directors shall be elected or replaced at the general meeting and may be removed by the general meeting before the expiration of their term of office. A Director shall serve a term of three years and can be re-elected upon the expiry of the tenure.

Reference is made to the announcement of the Company dated June 1, 2026. The original term of office of the Directors of the second session of the Board will expire on 21 September 2026. Pursuant to the Articles of Association, the Company has completed the procedures for nomination of Director candidates for the third session of the Board, and on June 1, 2026, the Board has resolved to:

(i) nominate Dr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming and Ms. NI Xiaomei to be re-elected as executive Directors;

(ii) nominate Ms. WAN Yunyun to be elected as an executive Director;

(iii) nominate Dr. JIANG Xiao and Mr. FUNG Che Wai Anthony to be re-elected as independent non-executive Directors;

(iv) nominate Dr. GONG Yan to be elected as an independent non-executive Director.

(each as a "**Candidate Director**", and collectively as the "**Candidate Directors**")

The biographical details of the Candidate Directors are set out in Appendix I to this circular.

The above proposal on re-election and election were made by the nomination committee of the Company (the "**Nomination Committee**") in accordance with the Board diversity policy and the nomination policy adopted by the Company based on the needs of the Company. It was submitted to the Board for consideration after the Nomination Committee having examined the relevant experience, skill and expertise of the Candidate Directors, and will be submitted by the Board to the AGM for final approval.

Subject to the approval by the shareholders at the AGM, the term of office of each Candidate Director shall be three years, with effective from the date of approval of their appointment by the shareholders at the AGM, and they shall be eligible for re-election upon the expiry of their term of office.

7. Re-election of the Supervisory Committee

An ordinary resolution will be proposed at the AGM to consider and approve the resolution on the re-election of shareholder representative Supervisors for the third session of the Supervisory Committee.

Pursuant to Article 137 of the Articles of Association, each Supervisor of the Company's Supervisory Committee shall serve a term of three years. Upon expiration of their term, Supervisors may serve consecutive terms if re-elected. Pursuant to Article 143 of the Articles of Association, the Supervisory Committee consists of three Supervisors, including one employee representative Supervisor. Shareholders' representatives of the Supervisory Committee shall be elected and removed by the general meeting, and employee representatives shall be democratically elected and removed by the employees of the Company through the employee representative' general meeting, employees' general meeting or other forms.

Reference is made to the announcement of the Company dated June 1, 2026. The original term of office of the Supervisors of the second session of the Supervisory Committee will expire on 21 September 2026. In accordance with the Articles of Association, The Supervisory Committee resolved on 1 June 2026 to nominate Mr. WEN Gang and Mr. CAI Xin for re-election as shareholder representative Supervisors (Each a "**Candidate Supervisor**", and collectively as the "**Candidate Supervisors**").

The biographical details of the Candidate Supervisors are set out in Appendix II to this circular.

The term of office of each Candidate Supervisor is three years, which shall commence from the date of approval by the Shareholders at the AGM and shall be eligible for re-election upon the expiry of the term of office. The shareholder representative Supervisors elected at the AGM and the employee representative Supervisors democratically elected by the employees of the Company shall together comprise the third session of the Supervisory Committee of the Company. The employee representative Supervisor of the third session of the Supervisory Committee will be democratically elected by the employees of the Company, and the Company will make a separate announcement in due course.

8. Consideration and approval of the remuneration plan for Directors for 2026

An ordinary resolution will be proposed at the AGM to consider and approve the remuneration plan for Directors for 2026, details of which are set out below.

Independent non-executive Directors, namely, Dr. JIANG Xiao, Mr. FUNG Che Wai Anthony and Dr. GONG Yan will be entitled to an annual remuneration of RMB180,000 (before tax), HKD240,000 (before tax) and RMB180,000 (before tax), respectively.

Executive Directors, namely, Dr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Ms. WAN Yunyun and Ms. NI Xiaomei, shall not receive any Directors' fees for their roles as Directors, but shall be entitled to remuneration based on their other employment positions in the Group and in accordance with the Company's internal policies.

Mr. HUANG Yufei, the current executive Director, and Dr. LI Zhiguo, the current independent non-executive Director, will not offer themselves for re-election as Directors of the third session of the Board at the AGM, and will cease to be Directors upon the election of the third session of the Board at the AGM. Their remuneration during their tenure as Directors in 2026 will be determined based on their actual period of service and the current remuneration policy of the Company, among which, HUANG Yufei will not receive any director's fee for his directorship, but is entitled to receive remuneration based on his other positions in the Group and in accordance with the internal policy of the Company; Dr. LI Zhiguo, as an independent non-executive Director, is entitled to receive director's remuneration based on his actual period of service, and such remuneration is calculated pro rata based on his original annual remuneration standard of RMB180,000 (before tax).

9. Consideration and approval of the remuneration plan for Supervisors for 2026

An ordinary resolution will be proposed at the AGM to consider and approve the remuneration plan for Supervisors for 2026, details of which are set out below.

Ms. DONG Xiaohan and Mr. CAI Xin, each a Supervisor, shall not receive any remuneration for their roles as Supervisors, but shall be entitled to remuneration, based on their other employment positions in the Group and in accordance with the Company's internal policies. Mr. WEN Gang, a Supervisor, shall not be entitled to any remuneration from the Company.

10. Consideration and approval of the financial budget for 2026

An ordinary resolution will be proposed at the AGM to consider and approve the financial budget of the Group for 2026. Based on the Company's financial results for 2025, the Company's target operating revenue for 2026 is approximately RMB0.608 billion.

Important note: The budget serves as the Company's internal management and control indicators for its operation plan for 2026, and does not represent its annual profit forecast. Achievement of indicators is conditional upon the corporate operation and management practices, market changes, macroeconomic environment and other internal and external factors, and is subject to uncertainty. Investors are advised to pay attention.

11. Consideration and approval of the re-appointment of the auditor of the Company and authorization to the Board to determine its remuneration

An ordinary resolution will be presented at the AGM to consider and approve the re-appointment of PricewaterhouseCoopers to serve as the external auditor of the Company for 2026 until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine its remuneration. Audit fees for 2026 are estimated to not exceed HK$3.98 million. The fees are estimated based on the complexity of the Group and business plans, the expected scope of the audit, the audit timetable and the resources required by the auditor.

Special Resolutions

12. Consideration and approval of the proposed granting of a general mandate to the Board to issue Shares

At the last annual general meeting of the Company held on June 13, 2025, a special resolution was passed by the then Shareholders to grant a general mandate to the Directors to exercise the powers of the Company to allot, issue and deal with additional Shares. Such mandate will lapse at the conclusion of the forthcoming AGM.

To provide more flexibility and convenience to fundraising activities by the Company, the following proposal to grant the Board a general mandate is hereby proposed at the AGM for consideration and approval:

A. The Board be granted a general mandate (the "**General Mandate**"), subject to terms and conditions set out in this resolution, for the exercise by the Board during the Relevant Period (as defined below) of powers to allot, issue and/or otherwise deal with additional H Shares and/or additional Domestic Shares in the share capital of the Company (including any sale or transfer of any treasury shares of the Company), and to make any proposals, enter into any agreement or grant any conversion rights in respect thereof, subject to the following terms:

(i) the General Mandate shall not extend beyond the Relevant Period save that the Board may, during the Relevant Period, make proposals, enter into any agreement or grant any conversion rights which might require the exercise of such powers after the end of the Relevant Period;

(ii) the total number of (a) new Shares to be allotted or agreed conditionally or unconditionally to be allotted and issued (whether or not by way of an exercise of conversion rights or by any other means) and (b) treasury shares to be sold/transferred by the Board shall not exceed 20% of the total number of Shares in issue as at the date of passing this resolution (excluding any treasury shares of the Company);

(iii) the Board will exercise its powers under the General Mandate only in accordance with the relevant laws and regulations of the PRC (as amended from time to time) and the Listing Rules and if all necessary filing procedures from the China Securities Regulatory Commission (中國證券監督管理委員會) and/or other relevant PRC government authorities are fulfilled;

(iv) for the purposes of this resolution:

"**Domestic Share(s)**" means the ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for in Renminbi;

"**H Share(s)**" means the overseas listed foreign ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange;

"**Relevant Period**" means the period from the passing of this resolution at the AGM until the earlier of:

(a) the conclusion of the next annual general meeting of the Company following the passing of this resolution at which time it shall lapse; or

(b) the date on which the authority conferred by this resolution is revoked or varied by a special resolution at a general meeting of the Company;

"**Share(s)**" means ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, including Domestic Share(s) and H Share(s).

B. Subject to the Board issuing additional Shares and/or any sale or transfer of any treasury shares of the Company pursuant to this resolution, the Board be authorized to:

(i) approve, execute and do or procure to be executed and done, all documents, deeds and things as it may consider necessary in connection with the issue of such new Shares and/or any sale or transfer of any treasury shares of the Company (including but not limited to the time, price, quantity and place of issue/sale/transfer, the filing of all necessary filings, registration and applications with or to relevant authorities in the PRC and/or Hong Kong (if applicable), and the entering into of an underwriting agreement or any other agreement (if applicable));

(ii) determine the use of proceeds;

(iii) determine the registered capital and the number of Shares pursuant to the issue or allotment of Shares pursuant to this resolution, and register with the relevant authorities in the PRC and/or Hong Kong upon an increase of registered capital and the number of Shares; and

(iv) make corresponding amendments to the Articles of Association as it thinks fit so as to reflect relevant matters, such as the registered capital and new capital structure of the Company after the issue and allotment of Shares.

13. Consideration and approval of the proposed granting of a general mandate to the Board to repurchase H Shares

At the last annual general meeting of the Company held on June 13, 2025, a special resolution was passed by the then Shareholders to grant a general mandate to the Directors to exercise the powers of the Company to repurchase Shares. Such mandate will lapse at the conclusion of the forthcoming AGM.

In order to give the Company the flexibility to repurchase H Shares if and when appropriate, a special resolution will be proposed at the AGM to consider and approve the granting of a general mandate to the Board to repurchase H Shares ("**H Share Repurchase Mandate**"), pursuant to which the Company may repurchase H Shares on the Stock Exchange of not exceeding 10% of the total number of issued H Shares of the Company as at the date of passing such resolution (excluding any treasury shares of the Company). Details of the H Share Repurchase Mandate are as follows:

A. The Board be granted a general mandate to determine to repurchase and deal with the H Shares, and to do all such acts, matters and business necessary or desirable for the purpose of or in connection with the exercise of the H Share Repurchase Mandate to repurchase H Shares, including but not limited to:

(i) formulating and implementing specific repurchase plans, including but not limited to determining the timing of repurchase, repurchase period, repurchase price, repurchase quantity, etc.;

(ii) notifying the creditors and making an announcement in accordance with the PRC Company Law and other relevant laws, regulations and normative documents and the Articles of Association;

(iii) opening overseas stock accounts and processing the corresponding foreign exchange change registration procedures;

(iv) fulfilling the relevant approval and filing procedures (if any) in accordance with the requirements of the regulatory authorities and the Stock Exchange;

(v) determining the specific use of repurchased H Shares (including but not limited to implementing equity incentives, reducing registered capital, etc.), and adjusting or changing the use of the repurchased H Shares as permitted by relevant laws and regulations based on the actual situation of the Company and within the time limit specified by relevant laws and regulations; and

(vi) executing and handling other documents and matters related to such repurchase.

Pursuant to the H Share Repurchase Mandate, the total number of H Shares that the Board is authorized to repurchase during the Relevant Period (as defined below) shall not exceed 10% of the total number of issued H Shares of the Company as at the date of passing this resolution (excluding any treasury shares of the Company).

B. The H Share Repurchase Mandate shall be subject to the fulfillment of all of the following conditions precedent:

(i) the obtaining of approvals from and/or the completion of filings with all competent regulatory authorities (if applicable) in accordance with the laws and regulations in the PRC; and

(ii) pursuant to the PRC Company Law and the notice procedures stipulated in the Articles of Association, in the event no creditor requires the Company to repay or provide security for any amount owed by the Company to the creditor, or if any of the Company's creditors requires the Company to repay or provide security, the Company has, at its sole and absolute discretion, made repayments or provided security for such amount. If the Company decides to repay any amount to any of its creditors, the Company will use internal funds to repay such amount.

C. The "**Relevant Period**" in this resolution refers to the period commencing on the date on which this resolution is considered and approved at the AGM, and ending at the earlier of:

(i) the conclusion of the next annual general meeting of the Company following the passing of this resolution at which time it shall lapse; or

(ii) the date on which the authority conferred by this resolution is revoked or varied by a special resolution at a general meeting of the Company.

An explanatory statement containing all relevant information relating to the H Share Repurchase Mandate to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the proposed granting of the H Share Repurchase Mandate to the Board is set out in Appendix III to this circular.

14. Consideration and approval of the proposed amendments to the Articles of Association

Reference is made to the announcement of the Company dated June 1, 2026.

In order to further improve the corporate governance of the Company, on June 1, 2026, the Board resolved to make slight adjustments to certain provisions in the Articles of Association after taking into consideration, among others, the operational and management needs of the Company.

The legal advisers of the Company as to Hong Kong laws and PRC laws have confirmed, respectively, that the proposed amendments to the Articles of Association are in compliance with the Listing Rules and applicable laws and regulations in the PRC. The Company also confirmed that there is nothing unusual about the proposed amendments to the Articles of Association for a company incorporated in the PRC and listed in Hong Kong.

Details of the proposed amendments to the Articles of Association are as follows (shown with underline to denote text to be added):

Before Amendments	After Amendments
Article 95 Directors shall be elected or replaced at the general meeting and may be removed by the general meeting before the expiration of their term of office. A Director shall serve a term of three years and can be re-elected upon the expiry of the tenure. The term of office of a Director shall start from the date on which the Director assumes office to the expiration of the term of office of the current Board. If the term of office of a Director expires but re-election is not made in a timely manner, the said Director shall continue to perform the duties as Director pursuant to laws, administrative regulations, departmental rules, the listing rules of the stock exchange where the Company's shares are listed and the Articles of Association until a new Director is elected.	**Article 95** Directors shall be elected or replaced at the general meeting and may be removed by the general meeting before the expiration of their term of office. A Director shall serve a term of three years and can be re-elected upon the expiry of the tenure. The term of office of a Director shall start from the date on which the Director assumes office to the expiration of the term of office of the current Board. Subject to compliance with the laws and regulations of the Company's place of incorporation and place of listing, as well as the listing rules of the stock exchange of the place of listing, during a single term of the Board, the cumulative number of Directors replaced upon the expiration of the current term (referring to the number of Directors replaced through election upon the

Before Amendments	After Amendments
A Director may be the general manager or other senior managers concurrently, provided that the total number of Directors who concurrently serve as the general manager or other senior managers and Directors who are employee representatives shall not exceed half of the total number of Directors of the Company.	expiration of the term) and Directors elected through by-elections or re-elections during the current term (referring to the number of Directors replaced due to by-elections or re-elections during the term) shall not exceed one-fourth (1/4) of the total number of Directors of the Board. However, the expiration of the term of office of independent Directors, resignation of Directors or inability to perform their duties, and removal of Directors from office due to violations of laws and regulations, etc. shall not be subject to such restriction. If the term of office of a Director expires but re-election is not made in a timely manner, the said Director shall continue to perform the duties as Director pursuant to laws, administrative regulations, departmental rules, the listing rules of the stock exchange where the Company's shares are listed and the Articles of Association until a new Director is elected. A Director may be the general manager or other senior managers concurrently, provided that the total number of Directors who concurrently serve as the general manager or other senior managers and Directors who are employee representatives shall not exceed half of the total number of Directors of the Company.

A special resolution will be proposed at the AGM to consider and approve the above matter and to authorize the Board to take all relevant actions and matters to give effect to such matter. The proposed amendments to the Articles of Association shall take effect upon approval by the Shareholders at the AGM.

The Articles of Association are prepared in Chinese without a formal English version. Therefore, any English translation shall be for reference only. In the event of any inconsistency, the Chinese version shall prevail. After the proposed amendments to the Articles of Association take effect, the full text of the revised Articles of Association will be published on the websites of the Stock Exchange and the Company.

III. AGM

The AGM of the Company will be held at 6th Floor, Building 24, Technology Oasis Phase 3, No. 1999 Yishan Road, Minhang District, Shanghai, PRC at 10:00 a.m. on Tuesday, June 23, 2026 to consider and, if thought fit, approve the resolutions as set out in the notice of the AGM. The notice of the AGM is set out in pages AGM-1 to AGM-4 of this circular and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.taimei.com).

IV. CLOSURE OF REGISTER OF MEMBERS OF H SHARES AND ASCERTAINING OF ELIGIBILITY OF ATTENDING THE AGM

The register of members of H Shares will be closed from Wednesday, June 17, 2026 to Tuesday, June 23, 2026, both days inclusive, during which no transfer of H Shares will be registered, in order to determine the holders of the H Shares who are entitled to attend and vote at the AGM. To be eligible to attend and vote at the AGM, all properly completed transfer documents in respect of H Shares, accompanied by relevant share certificate(s), must be lodged with the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17 Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong no later than 4:30 p.m. on Tuesday, June 16, 2026 for registration.

V. PROXY FORM

The proxy form for the AGM is enclosed with this circular and is published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.taimei.com).

If you intend to appoint a proxy to attend the AGM, you are required to duly complete the accompanying proxy form in accordance with the instructions printed thereon and return the same to the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at 3/F, Building 9, Smart Industry Innovation Park, 36 Changsheng South Road, Jiaxing, Zhejiang, PRC (for holders of Domestic Shares) as soon as possible and in any event not less than 24 hours before the time fixed for the holding of the AGM or any adjournment thereof (as the case may be) (which is 10:00 a.m. on Monday, June 22, 2026 (or other date in the event of any adjournment thereof)). Completion and return of the proxy form will not preclude you from attending and voting at the AGM or any adjournment thereof in person if you so wish.

VI. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at the AGM must be taken by poll. As such, the resolutions as set out in the notice convening the AGM will be voted by poll.

To the best knowledge and belief of the Directors, no Shareholder is deemed to have a material interest in the matters to be approved at the AGM and therefore, no Shareholder will be required to abstain from voting on any resolution at the AGM.

The announcement of the poll results of the AGM will be published at the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.taimei.com) after the conclusion of the AGM in accordance with the requirements of the Listing Rules.

VII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there is no other matter the omission of which would make any statement in this circular misleading.

VIII. RECOMMENDATION

The Directors (including the independent non-executive Directors) consider that all resolutions to be proposed at the AGM are in the best interests of the Company and the Shareholders as a whole. Therefore, the Directors recommend the Shareholders to vote in favor of all the resolutions to be proposed at the AGM.

IX. OTHER INFORMATION

Your attention is drawn to the additional information as set out in appendices to this circular.

Yours faithfully,
By Order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Dr. ZHAO Lu
Chairman of the Board

The biographical details of each Candidate Director are as follows:

PROPOSED EXECUTIVE DIRECTORS

Dr. ZHAO Lu (趙璐) ("Dr. ZHAO")

Dr. ZHAO Lu, aged 47, is the chairman of our Board and an executive Director. Dr. ZHAO joined our Group since January 2016 as the general manager and has served as a Director since December 2016. He was re-designated as an executive Director on September 21, 2023. Due to work re-arrangement, Dr. ZHAO ceased to be our general manager with effect from February 11, 2025, details of which are set out in the announcement of the Company dated February 11, 2025. Dr. ZHAO is also currently an executive director of Shanghai Taimei Xingyun Digital Technology Co., Ltd. (上海太美星雲數字科技有限公司), an executive director of Shanghai Taimei Xinghuan Digital Technology Co., Ltd. (上海太美星環數字科技有限公司), an executive director of Taimei Zhiyan Pharmaceutical R&D (Shanghai) Co., Ltd. (太美智研醫藥研發(上海)有限公司) ("**Taimei Zhiyan**"), an executive director of Hangzhou Taimei Xingcheng Pharmaceutical Technology Co., Ltd. (杭州太美星程醫藥科技有限公司) and an executive director and the general manager of Shanghai Taimei Xinghui Enterprise Management Co., Ltd. (上海太美星輝企業管理有限公司). He is primarily responsible for strategic planning, execution, operation and overall management of our Group.

Dr. ZHAO has more than 24 years of experience in the pharmaceutical and medical science industries. Prior to joining our Group, from August 2000 to March 2001, he was a technician and sales representative at Shanghai Sine Pharmaceuticals Co., Ltd. (上海信誼藥業有限公司), a pharmaceutical manufacturer, where he was primarily responsible for pharmaceutical sales. From March 2001 to April 2008, he was a product manager at the oncology and biotechnology products department at Schering-Plough (China) Co., Ltd. (先靈葆雅(中國)有限公司) (a subsidiary of Merck & Co., Inc. (formerly known as Schering-Plough Corporation) which is a multinational pharmaceutical company listed on the New York Stock Exchange (stock symbol: MRK)) in the PRC, where he was primarily responsible for pharmaceutical marketing. Besides, Dr. ZHAO was a co-founder of Shanghai Jsure Health Technology Co., Ltd. (上海捷信醫藥科技股份有限公司) (a digital patient solution provider in the pharmaceutical industry), and served as its director from June 2008 to January 2017 and deputy general manager from June 2008 to January 2016, where he was primarily responsible for formulation of business development strategies and market expansion.

Dr. ZHAO obtained his bachelor's degree in biotechnology and pharmacy jointly from Shenyang Pharmaceutical University (瀋陽藥科大學) in Liaoning and Jilin University (吉林大學) in Jilin in July 2000. He further obtained his executive master of business administration degree jointly from Fudan University (復旦大學) in Shanghai and National Taiwan University (國立台灣大學) in Taiwan, China in January 2019. In March 2026, Dr. ZHAO was conferred the degree of doctor of business administration by China Europe International Business School (Switzerland) (中歐國際工商學院(瑞士)).

Mr. MA Dong (馬東) ("Mr. MA")

Mr. MA Dong, aged 43, is an executive Director and the chief product officer of our Company. He joined our Group as the president of the digital R&D division in December 2014, and has been the chief product officer since February 2024. Since February 2025, he has acted as head of overseas business division of our Group. Mr. MA has further served as a Director since July 2017, and was re-designated as an executive Director on September 21, 2023. He is also currently an executive director and the general manager of Shanghai Taimei International Consulting Co., Ltd. (上海太美星際企業諮詢有限公司). He is primarily responsible for management and operation of overseas business department of our Group.

Mr. MA has more than 11 years of experience in clinical research and medical editorials. Prior to joining our Group, from August 2009 to August 2010, he was a project assistant at Shanghai Hengrui Pharmaceuticals Co., Ltd. (上海恒瑞醫藥有限公司), a company principally engaged in pharmaceutical R&D and a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600276)), where he was primarily responsible for formulation of clinical research protocols and project management. From November 2012 to May 2014, he was a clinical supervising associate at Parexel China Co., Ltd. (精鼎醫藥研究開發(上海)有限公司), a contract research organization, where he was primarily responsible for supervising clinical research. From May 2014 to December 2014, Mr. MA worked at WuXi Clinical Development Services (Shanghai) Co., Ltd. (上海康德弘翼醫學臨床研究有限公司) (formerly known as Shanghai Kangde Baorui Clinical Development Co., Ltd. (上海康德保瑞醫學臨床研究有限公司)), a contract research organization and a wholly-owned subsidiary of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (a company listed on the Stock Exchange (stock code: 2359)), where he was primarily responsible for designing clinical research protocols. He also previously worked at Shanghai THINK Advertising Co., Ltd. (上海欣可廣告有限公司) (a marketing service provider).

Mr. MA obtained his bachelor's degree in basic medicine from Fudan University (復旦大學) in Shanghai in July 2006. He further obtained his master's degree in pharmacology from Shanghai Institute of Pharmaceutical Industry (上海醫藥工業研究院) in Shanghai in June 2009 and his master's degree in business administration from the University of Hong Kong in Hong Kong in December 2020.

Mr. ZHANG Hongwei (張宏偉) ("Mr. ZHANG")

Mr. ZHANG Hongwei, aged 46, is an executive Director and the head of the digital marketing division of our Company. He joined our Group as the head of the digital marketing division since January 2015, and has served as strategic vice president of Taimei Zhiyan since October 2025. Mr. ZHANG has further served as a Director since February 2016, and was re-designated as an executive Director on September 21, 2023. He is primarily responsible for participating in the formulation and planning of the strategic development direction of Taimei Zhiyan, and empowering its business upgrading and value enhancement.

Mr. ZHANG has more than 11 years of experience in the pharmaceutical and medical industries. Prior to joining our Group, from September 2001 to December 2004, he was successively the head of the general manager's office at Shanghai Sine Pharmaceutical Equipment Co., Ltd. (上海信誼製藥裝備有限公司) (a pharmaceutical equipment manufacturer), an assistant to the general manager at Shanxi Xinyitong Pharmaceutical Co., Ltd. (山西信誼通製藥有限公司) (a company principally engaged in manufacturing and sales of pharmaceuticals and medical devices) and a deputy general manager at Shanghai Sine Pharmaceutical Equipment Co., Ltd.. From August 2010 to August 2012, he was a strategic development manager at Sanofi (China) Investment Co., Ltd. (賽諾菲(中國)投資有限公司), an investment management company. From September 2012 to February 2013, he was a manager at LEO Pharma Consultancy (Shanghai) Company Limited (上海勵奧醫藥諮詢有限公司), a company principally engaged in provision of medical consultancy services. From June 2013 to February 2014, Mr. ZHANG was a national manager of the patient support division at Bristol Myers Squibb (Shanghai) Trading Co., Ltd. (百時美施貴寶(上海)貿易有限公司), a company principally engaged in marketing and sales of pharmaceuticals, nutritional products and medical devices. From March 2014 to January 2015, he was a national manager of the patient management division at AstraZeneca Investment (China) Co., Ltd. (阿斯利康投資(中國)有限公司), a pharmaceutical company, where he was primarily responsible for patient management.

Mr. ZHANG obtained his college degree in pharmaceutical equipment from Shanghai University of Medicine & Health Sciences (上海健康醫學院) (formerly known as Shanghai Medical Equipment College (上海醫療器械高等專科學校)) in Shanghai in July 2001. He further obtained his master's degree in business administration from Fudan University (復旦大學) in Shanghai in January 2012.

Mr. LU Yiming (陸一鳴) ("Mr. LU")

Mr. LU Yiming, aged 44, is an executive Director and the chief technology officer of our Company. He joined our Group as the president of the R&D division in May 2018, and has been the chief technology officer since March 2024. Between January 2021 and March 2024, he was a Shareholders' representative Supervisor. Mr. LU was appointed as an executive Director on March 27, 2024. He is primarily responsible for management and operation of the R&D division of our Group.

Mr. LU has more than 15 years of experience in information technology and software engineering. Prior to joining our Group, from October 2008 to August 2011, he was a senior engineer at Microsoft Inc., a company listed on Nasdaq (stock symbol: MSFT), where he was primarily responsible for designs and R&D of the operating system of the company. From August 2011 to August 2015, he was a senior architect at Box Inc., a company listed on the New York Stock Exchange (stock symbol: BOX), where he was primarily responsible for R&D and system architecture of cloud services for file collaboration. Further, from September 2015 to April 2018, Mr. LU was a vice president of technology at Beijing Xieli Zhucheng Technology Information Services Co., Ltd. (北京協力築成科技資訊服務股份有限公司) (formerly known as Beijing Xieli Zhucheng Financial Information Service Co., Ltd. (北京協力築成金融資訊服務有限公司)), a company principally engaged in provision of media consultancy, corporate, financial information and venture capital services, where he was primarily responsible for the R&D and management of the company's media platform and venture financing platform. Mr. LU obtained his bachelor's degree in

computer science and technology from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 2003. He further obtained his master's degree in computer system structure from Shanghai Jiao Tong University (上海交通大學) in Shanghai and his master's degree in information and computer science from the University of California, Irvine in California in March 2006 and September 2008, respectively. Mr. LU is currently doing an executive master of business administration program at China Europe International Business School (中歐國際工商學院) in Shanghai.

Ms. NI Xiaomei (倪曉梅) ("Ms. NI")

Ms. NI Xiaomei, aged 55, is an executive Director, the legal director, the Board secretary and the joint company secretaries. She joined our Group as a deputy general manager, the legal director and the Board secretary in April 2018, and has been the legal director and the Board secretary since then. Ms. NI has further served as a Director since June 2018, and was re-designated as an executive Director on September 21, 2023. Ms. NI has been appointed as the joint company secretaries of the Company since July 31, 2023. Ms. NI is primarily responsible for securities-related and legal affairs of our Group and providing support to our Board.

Ms. NI has more than 18 years of experience in legal related matters. From March 2007 to April 2018, Ms. NI was a lawyer at Shanghai GF Law Firm (上海市廣發律師事務所), where she was primarily responsible for providing legal services on securities-related, financing and corporate matters.

Ms. NI obtained her bachelor's degree in industrial design from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 1992. She further obtained her master's degree in civil and commercial laws from East China University of Political Science and Law (華東政法大學) in Shanghai in December 2007. Ms. NI obtained her qualification of legal profession from the Ministry of Justice of the PRC (中華人民共和國司法部) in February 2007.

Ms. WAN Yunyun (萬韞鋆) ("Ms. WAN")

Ms. WAN Yunyun, aged 41, was appointed as our general manager on February 11, 2025. Ms. WAN joined the Group in February 2016 as a vice president of the business development division of the Company. From October 2019 to June 2023, Ms. WAN was the president of the business-to-business division of the Company. Since June 2023, she has been the president of the digital services division, a senior vice president and the chief commercial officer of the Company. Ms. WAN is also currently the general manager of a subsidiary of the Company, Shanghai Taimei Xingyun Digital Technology Co., Ltd. (上海太美星雲數字科技有限公司). She is primarily responsible for management and operation of the digital services division of the Group.

Ms. WAN has more than 16 years of experience in the pharmaceutical and medical science industries. Prior to joining the Group, from July 2005 to March 2006, she was an electronic engineer at Compal Electronics Technology (Kunshan) Co., Ltd. (仁寶電子科技(崑山)有限公司), a company principally engaged in manufacturing of electronic devices, where she was primarily responsible for providing assistance in research. From March 2006 to July 2009, she was a client manager at Shanghai Betterway Marketing Services Co., Ltd. (上海百達輝琪營銷服務有限公司), a company principally engaged in provision of advertising services, where she was primarily responsible for project management. From September 2009 to February 2016, she was a vice president of business development and a supervisor of Shanghai Jsure Health Technology Co., Ltd. (上海捷信醫藥科技股份有限公司), a digital patient solution provider in the pharmaceutical industry, where she was primarily responsible for sales of products to enterprises.

Ms. WAN graduated with a major in public relations from Fudan University (復旦大學) in Shanghai in January 2010. She obtained her master's degree in business administration from Fudan University in Shanghai in January 2020 and her master's degree in business administration from China Europe International Business School (中歐國際工商學院) in Shanghai in November 2023. Ms. WAN further obtained her executive master of business administration in hospitality jointly from China Europe International Business School in Shanghai and EHL Hospitality Business School in Switzerland in April 2024.

PROPOSED INDEPENDENT NON-EXECUTIVE DIRECTORS

Dr. JIANG Xiao (蔣驍) ("Dr. JIANG")

Dr. JIANG Xiao, aged 48, joined our Group since September 2020 as an independent Director and was re-designated as an independent non-executive Director on September 21, 2023. He is primarily responsible for providing independent advice and judgment to our Board.

Dr. JIANG has over 22 years of experience in investment and asset appraisal industries. From February 2003 to July 2024, he worked at and last served as the president and a director of Shanghai Orient Appraisal Co., Ltd. (上海東洲資產評估有限公司) ("**Shanghai Orient**"), a company principally engaged in provision of business valuation and asset appraisal services. He was also a director of Zhoulan Valuation Technology Research (Wuxi) Co., Ltd. (洲瀾估值技術研究(無錫)有限公司) from February 2022 to November 2023 and a director of Zhoulan (Shanghai) Asset Appraisal Co., Ltd. (洲藍(上海)資產評估有限公司) from April 2022 to March 2024, both of which are subsidiaries of Shanghai Orient. From October 2005 to December 2019, he was an executive director of Shanghai Hui Zhi Enterprise Management Consulting Co., Ltd. (上海輝智企業管理諮詢有限公司), a management consultancy firm. From April 2016 to April 2022, Dr. JIANG was an independent director of Angel Yeast Co., Ltd. (安琪酵母股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600298). From December 2018 to December 2021, he was an independent director of Welltrans O&E Co., Ltd. (武漢微創光電股份有限公司), a company listed on the Beijing Stock Exchange (stock code: 430198). From November 2017 to June 2021, Dr. JIANG was an executive director of Shanghai BroadMesse International Creative & Technology Co., Ltd. (上海寬創國際文化科技股份有限公司), a company principally engaged

in provision of design, fabrication, installation and technology solutions for exhibitions and events. From June 2020 to May 2026, he has been an independent director of Techstorm Advanced Material Corporation Limited (道生天合材料科技(上海)股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601026). From September 2022 to December 2025, he served as an independent director of Jinbei Automobile Co., Ltd. (金杯汽車股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600609). From February 2024 to October 2025, he served as an independent director of Tianfeng Securities Co., Ltd. (天風證券股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601162). From June 2021 to December 2022, he was an executive director of Shanghai Zhoulan Technology Co., Ltd. (上海洲瀾科技有限公司), a wholly-owned subsidiary of Shanghai Orient principally engaged in R&D and provision of enterprise consulting services with intelligent solutions. Since November 2022, Dr. JIANG has also been a director of Zhoulan Heyuan (Shanghai) Enterprise Service Co., Ltd. (洲藍郃願(上海)企業服務有限公司), an asset appraisal firm. Since July 2024, he has served as the chairman of the board of directors of Jinzheng (Shanghai) Asset Appraisal Co., Ltd. (金證(上海)資產評估有限公司), a company principally engaged in provision of business valuation and asset appraisal services, where he has been primarily responsible for overseeing the daily management and operation of the company. Besides, Dr. JIANG has been an independent director of Shanghai Friendess Electronic Technology Corporation Limited (上海柏楚電子科技股份有限公司), a company listed on the Shanghai Stock Exchange STAR Market (stock code: 688188), since June 2024.

Dr. JIANG obtained his bachelor's degree in economics and master's degree in economics from Soochow University (蘇州大學) in Jiangsu in June 2000 and July 2003, respectively. Dr. JIANG further obtained his doctor's degree in management from Business School Netherlands in the Netherlands in September 2016. Dr. JIANG obtained his qualification as an asset appraiser from the China Appraisal Society (中國資產評估協會) in June 2008.

Mr. FUNG Che Wai Anthony (馮志偉) ("Mr. FUNG")

Mr. FUNG Che Wai Anthony, aged 57, was appointed as an independent non-executive Director on September 21, 2023. He is primarily responsible for providing independent advice and judgment to our Board.

Mr. FUNG has more than 33 years of experience in the accounting, consulting services, investor relations and financial management. From August 1992 to September 1999, Mr. FUNG was an auditor at Deloitte Touche Tohmatsu, an accounting firm, where he was primarily responsible for providing audit services. From October 1999 to August 2007, he was a director of Winsmart Consultants Limited (弘陞投資顧問有限公司), a financial consulting firm, where he was primarily responsible for advising on pre-listing matters. From January 2008 to August 2010, he was a vice president of NagaCorp Ltd. (金界控股有限公司), a company listed on the Stock Exchange (stock code: 3918), where he was primarily responsible for investor relations matters. From January 2011 to July 2014, he was the chief financial officer and company secretary of Zall Smart Commerce Group Ltd. (卓爾智聯集團有限公司), a company listed on the Stock Exchange (stock code: 2098), where he was primarily responsible for financial management. From July 2014 to April 2017, Mr. FUNG served as the chief financial officer and company secretary of Kong Sun Holdings Limited (江山控股有限公司), a company listed on the Stock Exchange (stock code:

295), where he was primarily responsible for financial management. From May 2017 to December 2022, he was the chief financial officer and company secretary of Beijing Enterprises Urban Resources Group Limited (北控城市資源集團有限公司), a company listed on the Stock Exchange (stock code: 3718), where he was primarily responsible for financial management. Mr. FUNG also served as an independent non-executive director of FY Financial (Shenzhen) Co., Ltd. (富銀融資租賃(深圳)有限公司) (a company listed on the Stock Exchange (stock code: 8452)) from April 2017 to August 2023, and S&P International Holding Limited (椰豐集團有限公司) (a company listed on the Stock Exchange (stock code: 1695)) from June 2017 to October 2021, and Dekon Food and Agriculture Group (四川德康農牧食品集團股份有限公司) (a company listed on the Stock Exchange (stock code: 2419)) from October 2023 to February 2026, where he was primarily responsible for providing independent advice to the board of directors of the aforementioned companies.

Besides, Mr. FUNG has been an independent non-executive director of KWG Living Group Holdings Limited (合景悠活集團控股有限公司) (a company listed on the Stock Exchange (stock code: 3913)) since October 2020, Zhong An Group Limited (眾安集團有限公司) (a company listed on the Stock Exchange (stock code: 672)) since November 2021, XXF Group Holdings Limited (喜相逢集團控股有限公司) (a company listed on the Stock Exchange (stock code: 2473)) since October 2023, and Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司) (a company listed on the Stock Exchange (stock code: 2509)) since January 2024, where he has been primarily responsible for providing independent advice to the board of directors of the aforementioned companies.

Mr. FUNG obtained his bachelor's degree in accounting from The Hong Kong Polytechnic University (formerly known as Hong Kong Polytechnic) in Hong Kong in October 1992. Mr. FUNG has been a fellow of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants since October 2001 and September 2005, respectively.

Dr. GONG Yan (龔焱) ("Dr. GONG")

Dr. GONG Yan, aged 52, is proposed to be appointed as an independent non-executive Director in June 2026. Dr. GONG will be primarily responsible for providing independent opinion and judgment to the Board.

Dr. GONG served as an assistant professor at the University of California, Irvine (加州大學爾灣分校) from July 2007 to June 2013, specializing in corporate strategic transformation, lean entrepreneurship and business model innovation. He has been working at the China Europe International Business School (中歐國際工商學院) since July 2013, where he currently serves as a professor of management practice. From May 2016 to May 2023, he served as an independent director of Giant Network Group Co., Ltd. (巨人網絡集團股份有限公司) (Shenzhen Stock Exchange stock code: 002558). He has been an independent director of Gamehaus Holdings Inc.(家游控股有限公司) (Nasdaq Stock Exchange stock symbol: GMHS) since January 2025.

Dr. GONG obtained his bachelor's degree in engineering from Hunan University (湖南大學) in the PRC in July 1994, his master's degree in business administration from Zhejiang University (浙江大學) in the PRC in March 2001, and his doctor's degree from the University of Wisconsin-Madison in the United States in August 2007.

Dr. JIANG, Mr. FUNG and Dr. GONG have each confirmed that (i) they meet each of the independence factors set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) they have no past or present financial or other interests in the business of the Company or its subsidiaries, or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect their independence at the time of their appointment.

In considering the proposed independent non-executive Directors for the third session of the Board, the Nomination Committee has taken into account the independence confirmations of Dr. JIANG, Mr. FUNG and Dr. GONG, as well as their skills, background, knowledge and experience. In particular, Dr. JIANG has extensive experience in the investment and asset valuation industry, Mr. FUNG has extensive experience in accounting, advisory services, investor relations and financial management, and Dr. GONG has extensive experience in corporate strategic transformation, lean entrepreneurship, and business model innovation. Their diverse educational backgrounds, professional expertise and practice enable them to provide relevant and valuable insights and contribute to the diversity of the Board.

FURTHER DETAILS REGARDING THE PROPOSED RE-ELECTION AND ELECTION OF DIRECTORS

The proposed appointment of the Candidate Directors is subject to the approval of the Shareholders at the AGM. The Company proposes to enter into a service contract with each of the Candidate Directors for a term of three years commencing on the date of appointment approved by the AGM. The term of office of the Candidate Directors will be subject to the provisions of the Articles of Association, and shall be eligible for re-election upon the expiry of their term of office.

Upon the appointment of the Candidate Directors being approved by the Shareholders at the AGM, the re-elected Directors will continue to perform their existing duties, and the newly elected Directors will assume their corresponding responsibilities with effect from their appointments, while Dr. JIANG, Mr. FUNG and Dr. GONG, as proposed independent non-executive Directors, will be primarily responsible for providing independent advice to the Board.

The remuneration of the Directors is determined based on industry conditions as well as the scale and actual circumstances of the Company. Dr. ZHAO, Mr. MA, Mr. ZHANG, Mr. LU, Ms. NI and Ms. WAN will not receive any remuneration for serving as executive Directors. Dr. ZHAO, Mr. MA, Mr. ZHANG, Mr. LU, Ms. NI and Ms. WAN currently hold other positions in the Company and will receive remuneration in respect of such other positions they hold in the Company. The remuneration of Dr. ZHAO, Mr. MA, Mr. ZHANG, Mr. LU, Ms. NI and Ms. WAN will be determined in accordance with the relevant remuneration and assessment policies of the Company based on the specific positions they hold in the Company. The relevant remuneration will be determined with reference to their duties, experience,

positions, individual performance, the Group's results, and prevailing market levels. The Company will disclose the specific details of the annual remuneration in its annual report to be published each year. Dr. JIANG, Mr. FUNG and Dr. GONG, as independent non-executive Directors, will be entitled to receive an annual remuneration of RMB180,000 (before tax), HK$240,000 (before tax) and RMB180,000 (before tax), respectively.

As at the Latest Practicable Date, the total number of issued shares of the Company is 563,779,000 shares, comprising 363,186,467 domestic shares and 200,592,533 H shares.

As at the Latest Practicable Date, under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"), Dr. ZHAO has a long position in an aggregate of 145,840,149 shares and underlying shares, representing approximately 25.87% of the total number of issued shares of the Company, comprising: (i) 93,042,388 domestic shares; (ii) 45,503,584 domestic shares held through corporations controlled by him; (iii) 6,077,677 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026; and (iv) 1,216,500 H shares held through corporations controlled by him. Among such shares, Dr. ZHAO has an interest in an aggregate of 138,545,972 domestic shares, representing approximately 38.15% of the total number of issued domestic shares of the Company; and has an interest in an aggregate of 7,294,177 H shares and underlying H shares, representing approximately 3.64% of the total number of issued H shares of the Company.

As at the Latest Practicable Date, under Part XV of the SFO, Mr. ZHANG has a long position in an aggregate of 20,347,893 shares and underlying shares, representing approximately 3.61% of the total number of issued shares of the Company, comprising: (i) 20,312,190 domestic shares held through corporations controlled by him; and (ii) 35,703 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026. Among such shares, Mr. ZHANG has an interest in 20,312,190 domestic shares, representing approximately 5.59% of the total number of issued domestic shares of the Company; and has an interest in 35,703 underlying H shares, representing approximately 0.02% of the total number of issued H shares of the Company.

As at the Latest Practicable Date, under Part XV of the SFO, Mr. MA has a long position in 593,680 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.11% of the total number of issued shares of the Company and approximately 0.30% of the total number of issued H shares of the Company.

As at the Latest Practicable Date, under Part XV of the SFO, Mr. LU has a long position in 1,818,820 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.32% of the total number of issued shares of the Company and approximately 0.91% of the total number of issued H shares of the Company.

As at the Latest Practicable Date, under Part XV of the SFO, Ms. NI has a long position in 1,388,772 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.25% of the total number of issued shares of the Company and approximately 0.69% of the total number of issued H shares of the Company.

As at the Latest Practicable Date, under Part XV of the SFO, Ms. WAN has a long position in an aggregate of 41,496,851 shares and underlying shares, representing approximately 7.36% of the total number of issued shares of the Company, comprising: (i) 39,657,056 domestic shares held through corporations controlled by her; and (ii) 1,839,795 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026. Among such shares, Ms. WAN has an interest in 39,657,056 domestic shares, representing approximately 10.92% of the total number of issued domestic shares of the Company; and has an interest in 1,839,795 underlying H shares, representing approximately 0.92% of the total number of issued H shares of the Company.

The underlying H shares under the 2026 H Share Award Scheme mentioned above are all underlying H shares relating to unvested awards that have not yet been vested. As at the Latest Practicable Date, such awards have not yet been vested and are subject to the satisfaction of the relevant vesting conditions before they can be vested.

As at the Latest Practicable Date, save as disclosed above, each Candidate Director (i) does not hold any position in any other member of the Group; (ii) does not have any relationship with any Director, Supervisor, senior management member, or substantial or controlling shareholder of the Company; (iii) has not held any directorship in any other listed public company in the past three years; and (iv) does not have or is not deemed to have any interest or short position in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in Part XV of the SFO).

As at the Latest Practicable Date, save as disclosed above, the Board is not aware of any other matters relating to the appointment of the Candidate Directors that need to be brought to the attention of the Shareholders, nor is there any other information that is required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules.

The biographical details of each Candidate Supervisor are as follows:

Mr. WEN Gang (文綱) ("Mr. WEN")

Mr. WEN Gang, aged 48, has been a Shareholders' representative Supervisor since September 2020. He is primarily responsible for the supervision of the performance of our Directors and members of our senior management in performing their duties to our Company and performing other supervisory duties as a Supervisor.

Mr. WEN has more than 11 years of experience in investment. From June 2015 to October 2020, Mr. WEN was a supervisor of Beijing Kangfujiahe Medical Equipment Co., Ltd. (北京康福嘉和醫療器械有限公司).

Besides, since November 2013, Mr. WEN has also been a partner of Ningbo Free Trade Zone Kaifeng Venture Capital Management Co., Ltd. (寧波保税區凱風創業投資管理有限公司), an investment company, where he has been primarily responsible for managing investments in the biomedical sector. Besides, Mr. WEN is also currently a director of Beijing Kaifeng Jingde Management Consulting Co., Ltd. (北京凱風景德管理諮詢有限公司) (a business consultancy firm), Sinovation (Beijing) Medical Technology Co., Ltd. (華科精準(北京)醫療科技有限公司) (a company principally engaged in development of medical robotics and intelligent medical products), Neuracle Technology (Changzhou) Co., Ltd. (博睿康科技(常州)股份有限公司) (a company principally engaged in R&D, production, sales and technical service of brain computer interface and medical neuro-electrophysiological equipment), Hangzhou Bioeast BioTech Co., Ltd (杭州博岳生物技術有限公司) (a company principally engaged in provision of molecular diagnostic reagents and kits for medical science industries), Fang Cun Quan Xiang (Beijing) Technology Co., Ltd. (方寸泉香(北京)科技有限公司) (an internet medical service provider), InsureSmart (Shanghai) Intelligent Technology Co., Ltd. (因朔桔(上海)智能科技有限公司) (an artificial intelligence technology application service provider with a focus on the healthcare and insurance industries), YW MEMS (Suzhou) Co., Ltd. (蘇州原位芯片科技有限責任公司) (a company principally engaged in design and manufacturing of microelectromechanical systems chips), Shanghai Yinlu Information Technology Co., Ltd. (上海飲露信息科技有限公司) (a company principally engaged in provision of healthcare venture capital advisory services), Beijing Jingyilin International Hospital Management Co., Ltd. (北京菁醫林國際醫院管理有限公司) (a company principally engaged in provision of medical and healthcare services), Hangzhou Tiaoding Data Co., Ltd. (杭州調鼎數據有限公司) (a company principally engaged in providing intelligent information solutions for hospital health management and physical examination centers), Beijing Yaputuo Medical Technology Co., Ltd. (北京亞普拓醫療科技股份有限公司) (a company principally engaged in provision of private healthcare services), Red Cloud Bio Co., Ltd. (南京紅雲生物科技有限公司) (a small molecule drug discovery and development biotech company), Gege Medical Technology (Shanghai) Co., Ltd. (格格醫療科技(上海)有限公司) (a technology-based healthcare services provider) and Wuhan Tian Shi Wei Biotech Co., Ltd. (武漢天時維控股有限公司) (a manufacturer of soluble microcrystalline skin care products).

Mr. WEN obtained his bachelor's degree in clinical medicine and his master's degree in clinical medicine in July 2000 and July 2003, respectively, from Peking Union Medical College (北京協和醫學院) (formerly known as China Union Medical College (中國協和醫科大學)) in Beijing.

Mr. CAI Xin (蔡鑫) ("Mr. CAI")

Mr. CAI Xin, aged 45, is a Shareholders' representative Supervisor. He joined our Group as a deputy director of the image delivery center of commercial operations division of our Company in September 2017, and was the director of the same center between April 2018 and February 2024. He has been our vice president and the head of the image delivery center of commercial operations division since February 2024. Further, Mr. CAI has been our Supervisor since March 2024. As our Supervisor, he is primarily responsible for the supervision of the performance of our Directors and members of our senior management in performing their duties to our Company and performing other supervisory duties as a Supervisor.

Mr. CAI has more than 16 years of experience in the pharmaceutical industry. Prior to joining our Group, from December 2008 to October 2013, he was a research associate at Washington University in St. Louis in the United States. From October 2013 to May 2015, he was a project manager at Hangzhou Tigermed Consulting Co., Ltd (杭州泰格醫藥科技股份有限公司), a company listed on the Stock Exchange (stock code: 3347) and the Shenzhen Stock Exchange (stock code: 300347), where he was primarily responsible for project management.

From June 2015 to September 2017, Mr. CAI was a client operations manager at Parexel China Co., Ltd. (精鼎醫藥研究開發(上海)有限公司), a contract research organization, where he was primarily responsible for project management and customer support.

Mr. CAI obtained his bachelor's degree in computer science and technology from Wuhan University (武漢大學) in Hubei in June 2002. He further obtained his master's degree in biomedical engineering from Huazhong University of Science and Technology (華中科技大學) in Hubei and his master's degree in business administration from Fudan University (復旦大學) in Shanghai in December 2008 and June 2024, respectively.

FURTHER DETAILS REGARDING THE PROPOSED RE-ELECTION OF SUPERVISORS

The proposed appointment of the Candidate Supervisors is subject to the approval of the Shareholders at the AGM. The Company proposes to enter into a service contract with each of the Candidate Supervisors for a term of three years commencing on the date of appointment approved by the AGM. The term of office of the Candidate Supervisors shall be the same as stipulated in the Articles of Association, and upon expiry of the term, they shall be eligible for re-election.

Upon the appointment of the Candidate Supervisors being approved by the Shareholders at the AGM, the Candidate Supervisors who are re-elected will continue to perform their previous duties and functions. Mr. CAI Xin will not receive any remuneration for serving as a Shareholder representative Supervisor and will receive remuneration in accordance with the Company's relevant remuneration and assessment system, based on his other positions held in the Company; Mr. WEN Gang will not receive any remuneration for serving as a Shareholder representative Supervisor.

As at the Latest Practicable Date, save as disclosed above, each Candidate Supervisor (i) does not hold any position in any other member of the Group; (ii) does not have any relationship with any Director, Supervisor, senior management member, or substantial or controlling shareholder of the Company; (iii) has not held any directorship in any other listed public company in the past three years; and (iv) does not have or is not deemed to have any interest or short position in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in Part XV of the SFO).

As at the Latest Practicable Date, save as disclosed above, the Board is not aware of any other matters relating to the appointment of the Candidate Supervisors that need to be brought to the attention of the Shareholders, nor is there any other information that is required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules.

The following is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the special resolution to be proposed at the AGM in relation to the proposed granting of the H Share Repurchase Mandate.

1. REGISTERED CAPITAL

As at the Latest Practicable Date, the registered capital of the Company comprised 563,779,000 Shares, including 363,186,467 Domestic Shares and 200,592,533 H Shares, with a nominal value of RMB1.00 each. As at the Latest Practicable Date, the Company held 167,400 treasury shares.

2. EXERCISE OF THE H SHARE REPURCHASE MANDATE

Subject to the passing of the special resolution numbered 13 as set out in the notice of the AGM, the Board will be granted the H Share Repurchase Mandate until the earlier of:

(1) the conclusion of the next annual general meeting of the Company following the passing of the resolution granting the H Share Repurchase Mandate at the AGM; or

(2) the date on which the authority conferred by the resolution granting the H Share Repurchase Mandate is revoked or varied by a special resolution at a general meeting of the Company;

(the "**Relevant Period**").

The exercise of the H Share Repurchase Mandate is subject to, among others, the obtaining of approvals from and/or the completion of filings with all competent regulatory authorities (if applicable) in accordance with the laws and regulations in the PRC.

Subject to the passing of the resolution granting the H Share Repurchase Mandate and on the basis that no further Shares are issued or repurchased between the Latest Practicable Date and the AGM, the Company may repurchase pursuant to the H Share Repurchase Mandate a maximum of 20,042,513 H Shares, which represent approximately 10% of the total number of issued H Shares (excluding any treasury shares of the Company) as at the date of passing of the relevant resolution at the AGM.

3. REASONS FOR H SHARE REPURCHASE

The Directors believe that the granting of the H Share Repurchase Mandate is in the best interests of the Company and the Shareholders as a whole.

H Share repurchase may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share, and may also strengthen the investors' confidence in the Company and promote a positive effect on maintaining the Company's reputation in the capital market. Such repurchase will only be made when the Board believes that such a repurchase will benefit the Company and the Shareholders taken as a whole.

4. FUNDING OF H SHARE REPURCHASE

The Company intends to apply funds from the Company's internal resources (which may include surplus funds and retained profits) legally available for H Share repurchase in accordance with the Articles of Association, the Listing Rules and the applicable PRC laws and regulations. The amount of premium payable on repurchase may only be paid out of the profits of the Company before or at the time the H Shares are repurchased in the manner provided for under the PRC laws.

5. IMPACT OF SHARE REPURCHASE

Any repurchase of the H Shares by the Company may only be made either out of the funds of the Company that would otherwise be available for dividend or distribution or out of the proceeds of the issuance of new H Shares made for such purpose. The amount of financing required for the Company to purchase or acquire the H Shares, and the impact on the Company's financial position, could be ascertained as at the Latest Practicable Date as these will depend on whether the H Shares are purchased or acquired out of capital or profits, the number of H Shares purchased or acquired and the price at which such H Shares were purchased or acquired. There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited consolidated financial statements contained in the 2025 Annual Report) in the event that the H Share Repurchase Mandate is to be carried out in full at any time during the Relevant Period. However, the Directors do not intend to exercise the H Share Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital or the gearing levels of the Company which in the opinion of the Directors are from time to time appropriate for the Company.

6. MARKET PRICES OF H SHARES

The following table shows the highest and lowest prices at which the H Shares have been traded on the Stock Exchange during each of the previous twelve months preceding the Latest Practicable Date:

	Trading price per H Share	
Year & Month	**Highest**	**Lowest**
	HK$	*HK$*
2025		
May	3.780	3.280
June	3.640	3.310
July	4.970	3.310
August	5.310	4.300
September	5.070	4.070
October	5.000	3.960
November	4.550	3.780
December	4.000	3.610
2026		
January	4.970	3.710
February	4.990	4.600
March	5.100	4.180
April	4.860	4.190
May	4.950	4.180

7. GENERAL INFORMATION

None of the Directors nor, to the best of their knowledge and having made all reasonable enquiries, any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any H Shares to the Company if the H Share Repurchase Mandate is granted by the Shareholders at the AGM.

The Directors will exercise the power of the Company to repurchase H Shares pursuant to the H Share Repurchase Mandate in accordance with the Listing Rules and the applicable PRC laws and regulations.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any H Shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company if the H Share Repurchase Mandate is granted by the Shareholders at the AGM.

The Company may cancel such repurchased H Shares or hold them as treasury shares of the Company, subject to market conditions and the Group's capital management needs at the relevant time of the repurchases. For any treasury shares of the Company deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited ("**CCASS**") pending resale on the Stock Exchange, the Company shall (i) procure its broker not to give any instructions to Hong Kong Securities Clearing Company Limited to vote at general meetings of the Company for such treasury shares deposited with CCASS; (ii) in the case of dividends or distributions, withdraw such treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case, before the record date for the dividends or distributions; and (iii) take any other appropriate measures to ensure that it will not exercise any Shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable PRC laws if those Shares were registered in its own name as treasury shares.

The Company confirms that neither this explanatory statement nor the proposed H Share Repurchase Mandate has any unusual features.

8. TAKEOVERS CODE

If as a result of a repurchase of H Shares pursuant to the H Share Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code. The Directors are not aware of any consequences which would arise under the Takeover Code as a result of any repurchase of H Shares pursuant to the H Share Repurchase Mandate.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, Dr. ZHAO Lu (趙璐) ("**Dr. Zhao**") beneficially held 93,042,388 Domestic Shares. Dr. Zhao is the executive partner of Xinyu Haolin Enterprise Management Partnership (Limited Partnership) (新余浩霖企業管理合夥企業(有限合夥)) ("**Xinyu Haolin**"), Xinyu Qiwushi Medical Technology Partnership (Limited Partnership) (新余七武士醫療科技合夥企業(有限合夥)) ("**Xinyu Qiwushi**"), Xinyu Ruansu Enterprise Management Partnership (Limited Partnership) (新余軟素企業管理合夥企業(有限合夥)) ("**Ruansu Enterprise Management**"), Xinyu Taimei Nuoming Enterprise Management Partnership (Limited Partnership) (新余太美諾銘企業管理合夥企業(有限合夥)) ("**Xinyu Nuoming**") and Xinyu Taimei Xingmeng Enterprise Management Partnership (Limited Partnership) (新余太美星盟企業管理合夥企業(有限合夥)) ("**Xinyu Xingmeng**"), and is responsible for their respective management. As at the Latest Practicable Date, he also held approximately 74.94% partnership interest in Ruansu Enterprise Management. Further, Dr. Zhao is the general partner of Zhoushan Yijin Investment Management Partnership (Limited Partnership) (舟山憶瑾投資管理合夥企業(有限合夥)) ("**Zhoushan Yijin**") and Xinyu Shenkong Enterprise Management Partnership (Limited Partnership) (新余深空企業管理合夥企業(有限合夥)) ("**Xinyu Shenkong**"), and is

responsible for their respective management. As such, under the SFO, Dr. Zhao is deemed to be interested in the 45,503,584 Domestic Shares and 1,216,500 H Shares held by Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming, Xinyu Xingmeng, Zhoushan Yijin and Xinyu Shenkong. Therefore, Dr. Zhao is entitled to exercise the voting rights of 139,762,472 Shares of the Company, representing approximately 24.80% of the total issued share capital of the Company (excluding 167,400 treasury shares) prior to any exercise of the H Share Repurchase Mandate. In the event that the Directors exercise the proposed H Share Repurchase Mandate in full, the total shareholding and voting rights of the Company held by Dr. Zhao will increase to approximately 25.71% of the total issued share capital of the Company (excluding 167,400 treasury shares) (if he does not participate in the relevant repurchase). To the best knowledge and belief of the Directors, such increase will not give rise to an obligation to make a mandatory offer under the Takeovers Code. The Directors have no present intention to repurchase the H Shares to the extent that will trigger the obligations under the Takeovers Code.

The Listing Rules prohibit a company from making repurchase on the Stock Exchange if the repurchase would result in less than 25% (or such other prescribed minimum percentage as determined by the Stock Exchange) of the issued share capital being held in public hands. The Directors do not propose to repurchase H Shares which would result in the number of Shares in public hands falling below 25%.

9. H SHARE REPURCHASE MADE BY THE COMPANY

During the six months prior to the Latest Practicable Date, the Company has not repurchased any Shares (whether on the Stock Exchange or otherwise).

太美医疗科技

Zhejiang Taimei Medical Technology Co., Ltd.

浙江太美醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2576)

NOTICE OF THE 2025 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 2025 annual general meeting (the "**AGM**") of Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**") will be held at 6th Floor, Building 24, Technology Oasis Phase 3, No. 1999 Yishan Road, Minhang District, Shanghai, PRC at 10:00 a.m. on Tuesday, June 23, 2026 for the purposes of considering and, if thought fit, passing the following resolutions:

ORDINARY RESOLUTIONS

1. To consider and approve the work report of the board (the "**Board**") of directors (the "**Directors**") of the Company for 2025;

2. To consider and approve the work report of the supervisory committee of the Company (the "**Supervisory Committee**") for 2025;

3. To consider and approve the audited consolidated financial statements of Company and its subsidiaries for 2025;

4. To consider and approve the annual report of the Company for 2025;

5. To consider and approve the profit distribution plan for 2025;

6. To consider and approve the resolution on the re-election and election of Directors for the third session of the Board:

   (1) To re-elect Dr. ZHAO Lu as an executive Director;

   (2) To re-elect Mr. MA Dong as an executive Director;

   (3) To re-elect Mr. ZHANG Hongwei as an executive Director;

   (4) To re-elect Mr. LU Yiming as an executive Director;

(5) To re-elect Ms. NI Xiaomei as an executive Director;

(6) To elect Ms. WAN Yunyun as an executive Director;

(7) To re-elect Dr. JIANG Xiao as an independent non-executive Director;

(8) To re-elect Mr. FUNG Che Wai Anthony as an independent non-executive Director;

(9) To elect Dr. GONG Yan as an independent non-executive Director;

7. To consider and approve the resolution on the re-election of shareholder representative supervisors (the "**Supervisors**") for the third session of the Supervisory Committee:

(1) To re-elect Mr. WEN Gang as a shareholder representative Supervisor;

(2) To re-elect Mr. CAI Xin as a shareholder representative Supervisor;

8. To consider and approve the remuneration plan for Directors for 2026;

9. To consider and approve the remuneration plan for Supervisors for 2026;

10. To consider and approve the financial budget for 2026;

11. To consider and approve the re-appointment of PricewaterhouseCooper as the Company's auditor for 2026, and authorization to the Board to determine its remuneration;

SPECIAL RESOLUTIONS

12. To consider and approve the proposed granting of a general mandate to the Board to issue additional H shares and/or additional domestic shares of the Company;

13. To consider and approve the proposed granting of a general mandate to the Board to repurchase H shares of the Company; and

14. To consider and approve the proposed amendments to the Articles of Association of the Company.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Dr. ZHAO Lu
Chairman of the Board

Hong Kong, June 1, 2026

As at the date of this notice, the Board comprises Dr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.

Notes:

1. Closure of register of members of H shares of the Company ("H Shares") and ascertaining of eligibility for attending the AGM

The register of members of H Shares will be closed from Wednesday, June 17, 2026 to Tuesday, June 23, 2026, both days inclusive, during which no transfer of H Shares will be registered, in order to determine the holders of the H Shares who are entitled to attend and vote at the AGM. To be eligible to attend and vote at the AGM, all properly completed transfer documents in respect of H Shares, accompanied by relevant share certificate(s), must be lodged with the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17 Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong no later than 4:30 p.m. on Tuesday, June 16, 2026 for registration.

2. Proxy

(1) Each shareholder of the Company entitled to attend and vote at the AGM may appoint one or more proxies in writing to attend and vote at the meeting on his/her/its behalf. A proxy needs not be a shareholder of the Company.

(2) The instrument appointing a proxy must be in writing under the hand of the appointor or his/her attorney duly authorized in writing, or if the appointor is a legal entity, either under seal or signed by a director or a duly authorized attorney. If that instrument is signed by an attorney of the appointor, the power of attorney authorizing that attorney to sign or other document of authorization must be notarized.

(3) To be valid, the proxy form and notarized power of attorney or other document of authorization (if any) must be delivered to the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at 3/F, Building 9, Smart Industry Innovation Park, 36 Changsheng South Road, Jiaxing, Zhejiang, PRC (for holders of domestic shares of the Company) not less than 24 hours before the time fixed for the holding of the AGM or any adjournment thereof (as the case may be) (which is 10:00 a.m. on Monday, June 22, 2026 (or other date in the event of any adjournment thereof)). Completion and return of the proxy form will not preclude shareholders of the Company from attending and voting at the AGM should they so wish.

3. Registration procedures for attending the AGM

(1) Shareholders of the Company whose names appear on the register of members of the Company on June 23, 2026 will be entitled to attend and vote at the AGM or any adjournment thereof.

(2) A shareholder or his/her/its proxy should present proof of identity when attending the AGM. If a shareholder is a legal person, its legal representative or other person authorized by the board or other governing body of such shareholder may attend the AGM by providing a copy of the resolution of the board or other governing body of such shareholder appointing such person to attend the AGM.

(3) Where there are joint holders of any shares of the Company, any one of such joint holders may vote, either in person or by proxy, in respect of such shares of the Company as if he/she/it was solely entitled thereto; but if more than one of such joint holders are present at the AGM, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.

(4) Shareholders or proxies attending the AGM should state clearly, in respect of each resolution requiring a vote, whether they are voting for or against a resolution. The votes abstained will not be counted in the calculation of the required majority.

4. Voting method at the AGM

According to Rule 13.39(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, any vote of shareholders at a general meeting must be taken by poll. Accordingly, the chairman of the AGM will demand a poll in relation to all the proposed resolutions at the AGM.

5. Miscellaneous

(1) The AGM is expected to take no more than half a day. Shareholders who attend the AGM shall bear their own travelling and accommodation expenses.

(2) The address of the Company's H share registrar is:

17M Floor, Hopewell Centre
183 Queen's Road East
Wan Chai, Hong Kong

(3) The address of the Company's registered office and the contact details of the Company are:

3/F, Building 9
Smart Industry Innovation Park
36 Changsheng South Road
Jiaxing, Zhejiang, PRC

Telephone: +86 573 82682386
Email: ir@taimei.com

(4) References to times and dates in this notice are to Hong Kong local times and dates.

6. Arrangements for bad weather

The AGM may be postponed to a later date and/or time or cancelled if the AGM cannot be held due to bad weather. The Company will publish an announcement on the Stock Exchange's website (www.hkexnews.hk) and the Company's website (www.taimei.com) to notify shareholders of the Company of the date, time and place of the rescheduled meeting.